赛隆药业：子公司获右兰索拉唑化学原料药上市申请批准

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Hunan Sailong Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Rulanzoprazole, which is intended for treating bleeding gastric and duodenal ulcers when oral therapy is not suitable [1] Group 1 - The approval notification number for Rulanzoprazole is 2025YS01099, and it is valid until December 10, 2030 [1] - Rulanzoprazole injection will enhance the company’s raw material drug product pipeline [1] - There is uncertainty regarding the production and sales situation, and the company will disclose information as progress occurs [1]